LEF1 as a Prognostic Biomarker in Colorectal Cancer
Author Information
Author(s): Lin Albert Y., Chua Mei-Sze, Choi Yoon-La, Yeh William, Kim Young H., Azzi Raymond, Adams Gregg A., Sainani Kristin, van de Rijn Matt, So Samuel K., Pollack Jonathan R.
Primary Institution: Stanford University
Hypothesis
We sought to identify genes of clinical significance to predict survival and the risk for colorectal liver metastasis.
Conclusion
Overexpression of LEF1 in primary colorectal cancer is a prognostic factor for poor survival and increased risk for liver metastasis.
Supporting Evidence
- LEF1 overexpression was significantly correlated with liver metastasis.
- Patients with LEF1 overexpression had significantly worse survival rates.
- Stage of cancer was also identified as a significant prognostic marker.
Takeaway
This study found that a protein called LEF1 can help doctors predict how well patients with colorectal cancer will do, especially if their cancer spreads to the liver.
Methodology
Gene expression profiling was performed on specimens from primary colorectal cancer and liver metastases, followed by immunohistochemistry analysis on a tissue microarray.
Limitations
The study's findings may be limited by the modest sensitivity and specificity of LEF1 as a predictor for liver metastasis.
Participant Demographics
The study included 31 primary CRC specimens from 30 patients and 32 CLM specimens from 31 patients, with a mix of male and female participants across various ages.
Statistical Information
P-Value
p<0.01
Confidence Interval
1.09–2.89
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website